Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation.

High lipoprotein(a) [Lp(a)] plasma concentrations are an independent risk factor for atherosclerosis. In the general population, Lp(a) levels are primarily determined by allelic variation at the apolipoprotein(a) [apo(a)] gene locus. Apo(a) isoforms of various sizes are associated with different Lp(a) concentrations. Patients with end-stage renal disease (ESRD) have elevated plasma concentrations of Lp(a), which are not explained by the size variation at the apo(a) gene locus. To further investigate the origin of the elevated Lp(a) plasma concentrations, we examined Lp(a) concentrations and apo(a) phenotypes in 154 ESRD patients undergoing renal transplantation. In a prospective longitudinal study we observed a rapid normalization of Lp(a) levels from an average concentration of 25.9 +/- 28.7 mg/dL before to 17.9 +/- 25.5 mg/dL 3 weeks after renal transplantation (P < .0001). Only patients with high-molecular-weight phenotypes had a significant decrease in Lp(a) plasma concentrations. This study demonstrates the nongenetic origin of elevated Lp(a) concentrations in ESRD patients, which is obviously caused by the disease. It further confirms a phenotype-associated elevation of Lp(a) concentrations in ESRD.

[1]  D. Rowińska.  [Cardiovascular complications after renal transplantation]. , 1994, Polskie Archiwum Medycyny Wewnetrznej.

[2]  P. Morris.  Kidney Transplantation: Principles and Practice , 1994 .

[3]  M. Yacoub,et al.  Does cyclosporin affect lipoprotein(a) concentrations? , 1994, The Lancet.

[4]  P. Ridker,et al.  A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.

[5]  S. Dubrey,et al.  Effect of insulin-dependent diabetes mellitus on lipids and lipoproteins: a study of identical twins. , 1993, Clinical science.

[6]  S. Marcovina,et al.  Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. , 1993, Biochemical and biophysical research communications.

[7]  F. Kronenberg,et al.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.

[8]  M. Seed,et al.  Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? , 1993, The Lancet.

[9]  T. Shoji,et al.  High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. , 1992, Clinical nephrology.

[10]  R. Krauss,et al.  Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. , 1992, American Journal of Human Genetics.

[11]  E. Boerwinkle,et al.  Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  J. Fruchart,et al.  Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. , 1992, Kidney international.

[13]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[14]  E. Boerwinkle,et al.  Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. , 1992, The Journal of clinical investigation.

[15]  L. Raij,et al.  Cardiovascular risk factors in chronic renal failure and hemodialysis populations. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  G. Thorgeirsson,et al.  Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. , 1992, The American journal of cardiology.

[17]  P. McNamee,et al.  Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. , 1992, Atherosclerosis.

[18]  E. Boerwinkle,et al.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. , 1992, The Journal of clinical investigation.

[19]  D. Wilcken,et al.  Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. , 1992, Clinical chemistry.

[20]  M. Averna,et al.  Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis. , 1992, Nephron.

[21]  J. Huttunen,et al.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. , 1991, Atherosclerosis.

[22]  E. Boerwinkle,et al.  Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. , 1991, The Journal of clinical investigation.

[23]  B Budowle,et al.  Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. , 1991, American journal of human genetics.

[24]  L. Levitsky,et al.  Lipoprotein(a) Levels in Black and White Children and Adolescents With IDDM , 1991, Diabetes Care.

[25]  G. Appel,et al.  Lipid abnormalities in renal disease. , 1991, Kidney international.

[26]  L. Wilhelmsen,et al.  Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. , 1990, BMJ.

[27]  G. Utermann,et al.  Abetalipoproteinemia with an ApoB-100-lipoprotein(a) glycoprotein complex in plasma. Indication for an assembly defect. , 1990, The Journal of biological chemistry.

[28]  G. Assmann,et al.  Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. , 1990, Clinical chemistry.

[29]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[30]  M. Weintraub,et al.  HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. , 1989, Circulation.

[31]  M. Seishima,et al.  Transient changes of serum lipoprotein(a) as an acute phase protein. , 1989, Atherosclerosis.

[32]  E. Boerwinkle,et al.  Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Utermann,et al.  Lp(a) Phenotyping by Immunoblotting with Polyclonal and Monoclonal Antibodies , 1988, Arteriosclerosis.

[34]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.

[35]  J. Fruchart,et al.  Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. , 1987, Clinical chemistry.

[36]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[37]  A. Gotto,et al.  CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography , 2022 .

[38]  K. Pfeiffer,et al.  Fluctuations of plasma liproprotein-a concentrations during pregnancy and post partum , 1986 .

[39]  K. Pfeiffer,et al.  Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum. , 1986, Metabolism: clinical and experimental.

[40]  E Marth,et al.  Lipoprotein Lp(a) and the risk for myocardial infarction. , 1981, Atherosclerosis.

[41]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .